Last Updated : September 18, 2023
Details
Generic Name:
nelarabine
Project Status:
Active
Therapeutic Area:
T-cell acute lymphoblastic leukemia
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
Atriance
Project Line:
Reimbursement Review
Project Number:
PC0307-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Nelarabine
(Atriance) for addition to front-line multi-agent therapy of pediatric,
adolescent, and young adult (AYA) patients (aged 130 years at diagnosis) with
intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL).
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
Nelarabine (Atriance) for addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1–30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 30-Jan-23 |
|---|---|
| Call for patient/clinician input closed | 27-Mar-23 |
| Clarification: - Patient input submission received from Leukemia & Lymphoma Society of Canada | |
| Submission received | 06-Mar-23 |
| Submission accepted | 21-Mar-23 |
| Review initiated | 22-Mar-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 21-Jun-23 |
| Deadline for sponsors comments | 30-Jun-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 27-Jul-23 |
| Expert committee meeting (initial) | 09-Aug-23 |
| Draft recommendation issued to sponsor | 23-Aug-23 |
| Draft recommendation posted for stakeholder feedback | 31-Aug-23 |
| End of feedback period | 15-Sep-23 |
Last Updated : September 18, 2023